Physician profile
Devyn Ann Demaree
NPI 1649703257
$2,963.36
in general payments reported to CMS, 2019-2025
26 companies · $508 in 2025
The $508 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $434 · 2022: $604 · 2023: $863 · 2024: $555 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,912 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.34 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $324.72 | 2022-2025 | Veozah |
| Coopersurgical, INC. | $241.36 | 2021-2024 | Advincula Delineator Uterine Manipulator, Paragard T 380a, Summit Doppler |
| Sage Therapeutics, LLC | $235.57 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $196.61 | 2021-2023 | |
| Medtronic, INC. | $189.65 | 2022-2025 | Truclear |
| Mayne Pharma Commercial LLC | $188.97 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.16 | 2021-2023 | |
| Organon LLC | $159.32 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $154.77 | 2021-2025 | Novasure, Fluent Fluid Management System, Myosure Tissue Removal Device |
| Abbvie INC. | $152.61 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $145.70 | 2021-2025 | Exparel |
| Sumitomo Pharma America, INC. | $132.28 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $120.80 | 2021-2024 | Slynd |
| Myriad Women'S Health, INC. | $112.36 | 2023 | Myrisk |
| Millicent US INC | $109.48 | 2023-2024 | Femring, Intrarosa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $103.30 | 2021-2022 | |
| Dexcom, INC. | $40.75 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $39.90 | 2023-2024 | Accrufer |
| Ethicon US, LLC | $28.81 | 2024 | Ethicon, Dermabond Prineo, Stratafix |
| Supernus Pharmaceuticals, INC. | $24.25 | 2025 | Qelbree |
| Aspira Women'S Health INC | $18.92 | 2024 | Ova1 |
| Optumhealth Care Solutions, LLC | $18.59 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Evofem Biosciences, INC. | $17.40 | 2024 | |
| Exact Sciences Corporation | $15.63 | 2025 | Cologuard Collection Kit |
| Scynexis, INC. | $12.56 | 2022 | |
| Lupin INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devyn Demaree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.